Abstract: The present invention provides a method for determining in vitro, in a peripheral blood sample, the probability for an individual to suffer from a colorectal cancer, using the comparison of the amount of expression products of nucleic acids of genes of the individual to be tested with the amount of expression products of nucleic acids of the same genes obtained from a CRC group of patients constituting the positive control and with the amount of expression products of nucleic acids of the same genes obtained from a CNC group of individuals constituting the negative control; and a kit comprising specific binding partners for said expression products.

Abstract: A method and kit for the prognosis of colorectal cancer where the method includes the steps of: a) obtaining a peripheral blood sample and extracting total RNA from the sample, b) contacting the total RNA with at least one reagent specific for at least one NK cell gene and no more than 25 specific reagents for 25 NK cell genes, c) determining the expression level of at least one and at most 25 NK cell genes to obtain an expression profile for the patient, d) analyzing the expression profile with expression profiles previously clinically classified as a good prognosis and as a poor prognosis, wherein if the expression profile is clustered with the poor prognosis profiles, then the patient is determined to have a poor prognosis, and if the expression profile is clustered with the good prognosis profiles, then the patient is determined to have a good prognosis.

Abstract: A method and kit are related to discriminating between breast cancer and benign breast disease by the determination of the expression level of at least one target gene including a nucleic acid sequence selected from the nucleic acid sequences set forth in SEQ ID NOs: 1, 2 or 3, 4 and 5 or 6 to obtain an expression profile for the patient, and the comparison of the expression profile of the patient with expression profiles of target genes from patients previously clinically classified as breast cancer and expression profiles of target genes from patients previously clinically classified as benign breast disease.

Abstract: A flash memory device includes a cover, an electrical module, a slider and a rotatable member for driving the slider. The cover defines a receiving chamber and an opening communicating with the receiving chamber. The electrical module is slideably received in the receiving chamber and includes a circuit board and a connector port electrically connected with the circuit board. The rotatable member has a fixed axis around which the rotatable member revolves. The rotatable member includes a protrusion slideably received in a slot defined in the slider. The connector port is driven to telescopically extend through the opening by the slider which is further driven by the protrusion.

Abstract: A flash memory device includes a cover, an electrical module, a slider and a rotatable member for driving the slider. The cover defines a receiving chamber and an opening communicating with the receiving chamber. The electrical module is slideably received in the receiving chamber and includes a circuit board and a connector port electrically connected with the circuit board. The rotatable member has a fixed axis around which the rotatable member revolves. The rotatable member includes a protrusion slideably received in a slot defined in the slider. The connector port is driven to telescopically extend through the opening by the slider which is further driven by the protrusion.